Stocktoria
Prelude Therapeutics Inc PRLD
Prelude Therapeutics Inc (PRLD) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $12.1M at a -819.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.373 |
| Retained earnings / assets | -4.834 |
| EBIT / assets | -0.74 |
| Equity / liabilities | 0.944 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PRLD | Prelude Therapeutics Inc | 3/9 | -17.29 | — | — |
| JAGX | Jaguar Health, Inc. | 2/9 | — | — | -1.5% |
| EVMN | Evommune, Inc. | 2/9 | 9.47 | — | — |
| TNXP | Tonix Pharmaceuticals Holding Corp. | 3/9 | -0.37 | — | +29.8% |
| CBIO | CRESCENT BIOPHARMA, INC. | 4/9 | 4.59 | — | — |
| PYXS | Pyxis Oncology, Inc. | 2/9 | -16.86 | — | -14.2% |
| ABUS | Arbutus Biopharma Corp | 3/9 | — | — | — |
About Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
FAQ
Is PRLD financially healthy?
Prelude Therapeutics Inc's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does PRLD pay a dividend?
No, Prelude Therapeutics Inc does not currently pay a dividend.
How profitable is PRLD?
In FY2025, Prelude Therapeutics Inc had a net margin of -819.6% and a return on equity of -145.0%.
What is the analyst price target for PRLD?
The average Wall-Street price target for Prelude Therapeutics Inc is $8.00, about 39.6% above the recent price, from 3 analysts.
Is PRLD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Prelude Therapeutics Inc: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.